ASH® 2025 Highlights: Presenter Vignette – Jennifer Woyach
Jennifer Woyach
MD
The Ohio State University
683
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.
